Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | CTSE | P14091 | 2/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.33 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 7/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20749835 | 1.00 | CTSD (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL21782040 | 1.00 | CTSD (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL22618698 | 0.94 | SSTR2 (0.35) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL22561279 | 0.94 | CTSD (0.36) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL21137675 | 0.94 | SSTR2 (0.36) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL18602020 | 0.94 | CYP3A4 (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL15811693 | 0.94 | CYP3A4 (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL22419930 | 0.94 | CYP3A4 (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL19841574 | 0.94 | CYP3A4 (0.37) | CTSDCTSEBACE1SSTR2CYP3A4 | |
| SCHEMBL21781785 | 0.92 | SSTR2 (0.36) | CTSDCTSEBACE1SSTR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206872-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | Magenta Therapeutics, Inc. | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206872-A1 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD117+ CELLS | CD47, SIGLEC7, MYADM | CTSD 531/4885CTSE 606/4885BACE1 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.